Legato Capital Management LLC Lowers Stock Position in Regeneron Pharmaceuticals, Inc. $REGN

Posted by Geri Gentry on May 23rd, 2026

Legato Capital Management LLC lessened its holdings in Regeneron Pharmaceuticals, Inc. (NASDAQ:REGN – Free Report) by 13.7% in the 4th quarter, according to its most recent filing with the SEC. The firm owned 8,803 shares of the biopharmaceutical company’s stock after selling 1,400 shares during the period. Regeneron Pharmaceuticals comprises 0.6% of Legato Capital Management LLC’s holdings, making the stock its 20th biggest position. Legato Capital Management LLC’s holdings in Regeneron Pharmaceuticals were worth $6,795,000 as of its most recent SEC filing.

Other hedge funds have also recently modified their holdings of the company. Sound Shore Management Inc CT purchased a new stake in shares of Regeneron Pharmaceuticals in the 3rd quarter worth approximately $64,677,000. Ellerson Group Inc. ADV raised its stake in shares of Regeneron Pharmaceuticals by 49.2% during the 3rd quarter. Ellerson Group Inc. ADV now owns 8,102 shares of the biopharmaceutical company’s stock worth $4,556,000 after acquiring an additional 2,671 shares in the last quarter. Nordea Investment Management AB raised its stake in shares of Regeneron Pharmaceuticals by 118.1% during the 4th quarter. Nordea Investment Management AB now owns 137,321 shares of the biopharmaceutical company’s stock worth $105,810,000 after acquiring an additional 74,350 shares in the last quarter. Oppenheimer & Co. Inc. raised its stake in shares of Regeneron Pharmaceuticals by 7.2% during the 3rd quarter. Oppenheimer & Co. Inc. now owns 23,714 shares of the biopharmaceutical company’s stock worth $13,334,000 after acquiring an additional 1,597 shares in the last quarter. Finally, TD Asset Management Inc raised its stake in shares of Regeneron Pharmaceuticals by 15.9% during the 3rd quarter. TD Asset Management Inc now owns 374,264 shares of the biopharmaceutical company’s stock worth $210,437,000 after acquiring an additional 51,407 shares in the last quarter. Hedge funds and other institutional investors own 83.31% of the company’s stock.

Regeneron Pharmaceuticals Trading Down 0.6%

Shares of Regeneron Pharmaceuticals stock opened at $638.88 on Friday. The company has a current ratio of 3.57, a quick ratio of 2.96 and a debt-to-equity ratio of 0.06. Regeneron Pharmaceuticals, Inc. has a 12-month low of $476.49 and a 12-month high of $821.11. The firm has a market capitalization of $67.54 billion, a price-to-earnings ratio of 15.57, a PEG ratio of 1.42 and a beta of 0.30. The firm’s 50 day simple moving average is $731.45 and its two-hundred day simple moving average is $744.92.

Regeneron Pharmaceuticals (NASDAQ:REGN – Get Free Report) last issued its quarterly earnings results on Wednesday, April 29th. The biopharmaceutical company reported $9.47 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $8.91 by $0.56. Regeneron Pharmaceuticals had a net margin of 29.65% and a return on equity of 13.16%. The business had revenue of $3.61 billion for the quarter, compared to analyst estimates of $3.48 billion. During the same quarter in the prior year, the business posted $8.22 EPS. Regeneron Pharmaceuticals’s revenue for the quarter was up 19.0% compared to the same quarter last year. Analysts predict that Regeneron Pharmaceuticals, Inc. will post 37.25 EPS for the current year.

Regeneron Pharmaceuticals Dividend Announcement

The business also recently declared a quarterly dividend, which will be paid on Thursday, June 4th. Shareholders of record on Wednesday, May 20th will be paid a dividend of $0.94 per share. The ex-dividend date is Wednesday, May 20th. This represents a $3.76 dividend on an annualized basis and a yield of 0.6%. Regeneron Pharmaceuticals’s dividend payout ratio is presently 9.16%.

Insider Transactions at Regeneron Pharmaceuticals

In other Regeneron Pharmaceuticals news, Director Arthur F. Ryan sold 100 shares of the company’s stock in a transaction that occurred on Friday, May 1st. The shares were sold at an average price of $705.24, for a total transaction of $70,524.00. Following the transaction, the director owned 17,503 shares in the company, valued at approximately $12,343,815.72. This represents a 0.57% decrease in their position. The sale was disclosed in a document filed with the SEC, which can be accessed through the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Insiders own 6.97% of the company’s stock.

Wall Street Analyst Weigh In

Several research firms recently commented on REGN. JPMorgan Chase & Co. reduced their price objective on shares of Regeneron Pharmaceuticals from $950.00 to $850.00 and set an “overweight” rating for the company in a research note on Monday, May 18th. Oppenheimer reiterated an “outperform” rating and set a $865.00 price objective (up from $750.00) on shares of Regeneron Pharmaceuticals in a research note on Monday, February 2nd. Guggenheim boosted their price objective on shares of Regeneron Pharmaceuticals from $975.00 to $995.00 and gave the stock a “buy” rating in a research note on Friday, May 1st. Truist Financial reduced their price objective on shares of Regeneron Pharmaceuticals from $796.00 to $778.00 and set a “buy” rating for the company in a research note on Monday, May 18th. Finally, Wall Street Zen upgraded shares of Regeneron Pharmaceuticals from a “hold” rating to a “buy” rating in a research note on Saturday, May 2nd. Two equities research analysts have rated the stock with a Strong Buy rating, fifteen have issued a Buy rating and ten have issued a Hold rating to the stock. According to data from MarketBeat, the company has an average rating of “Moderate Buy” and a consensus price target of $792.65.

Get Our Latest Stock Analysis on Regeneron Pharmaceuticals

More Regeneron Pharmaceuticals News

Here are the key news stories impacting Regeneron Pharmaceuticals this week:

Positive Sentiment: Regeneron reported strong early results for Lynozyfic (linvoseltamab) in systemic AL amyloidosis, including rapid reductions in disease markers, a 100% complete response rate at the highest dose, and signs of improved heart and kidney function. The program remains investigational, but the data support a potential new growth opportunity. Article Title
Positive Sentiment: Regeneron also announced that the European Medicines Agency accepted its filing for Otarmeni (lunsotogene parvec) in genetic hearing loss, a regulatory step that could expand the company’s rare-disease pipeline in the EU if approved. Article Title
Neutral Sentiment: A Zacks piece highlighted REGN as a “strong value stock,” reflecting continued analyst support for the shares despite recent volatility. Article Title
Negative Sentiment: Investor alerts and law-firm announcements said they are investigating possible securities claims against Regeneron after its Phase 3 melanoma trial for fianlimab plus Libtayo missed its primary endpoint versus Keytruda, raising legal and execution concerns. Article Title
Negative Sentiment: Separate reports quoted Jim Cramer saying REGN could face more downgrades after the poor melanoma readout, reinforcing the market’s worry that the failed study may weigh on near-term sentiment. Article Title

About Regeneron Pharmaceuticals

(Free Report)

Regeneron Pharmaceuticals, Inc (NASDAQ: REGN) is a U.S.-based biotechnology company founded in 1988 and headquartered in Tarrytown, New York. It focuses on discovering, developing, manufacturing and commercializing medicines for serious medical conditions. The company combines laboratory research, clinical development and in-house manufacturing to advance a pipeline of biologic therapies across multiple therapeutic areas.

Regeneron is known for its proprietary drug discovery technologies, including its VelocImmune platform, which is used to generate fully human monoclonal antibodies.